Sarepta Therapeutics, Inc. (SRPT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 900M 1.8B 2.7B Q3 '21: 645.6M Q4 '21: 701.9M Q1 '22: 765.8M Q2 '22: 835.2M Q3 '22: 876M Q4 '22: 933M Q1 '23: 975.7M Q2 '23: 1B Q3 '23: 1.1B Q4 '23: 1.2B Q1 '24: 1.4B Q2 '24: 1.5B Q3 '24: 1.6B Q4 '24: 1.9B Q1 '25: 2.2B Q2 '25: 2.5B Q3 '25: 2.4B Q4 '25: 2.2B Q1 '26: 2.2B Q2 '26: 2B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 600M 1.2B 1.8B Q4 '24: 1.5B Q1 '25: 1.6B Q2 '25: 1.7B Q3 '25: 1.6B Q4 '25: 1B Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating Income TTM

-750M -500M -250M 0 250M 500M 750M Q3 '21: -524.6M Q4 '21: -459.7M Q1 '22: -394.7M Q2 '22: -438.3M Q3 '22: -535.2M Q4 '22: -536.2M Q1 '23: -587.4M Q2 '23: -509.8M Q3 '23: -399.3M Q4 '23: -267.8M Q1 '24: -94.8M Q2 '24: 38M Q3 '24: 81M Q4 '24: 218.1M Q1 '25: -117.2M Q2 '25: -932K Q3 '25: -126.5M Q4 '25: -699.8M Q1 '26: -41M Q2 '26: -143.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-1.2B -800M -400M 0 400M 800M 1.2B Q3 '21: -486.1M Q4 '21: -418.8M Q1 '22: -356.6M Q2 '22: -506.6M Q3 '22: -716.2M Q4 '22: -703.5M Q1 '23: -1.1B Q2 '23: -907.7M Q3 '23: -690.9M Q4 '23: -536M Q1 '24: 16.9M Q2 '24: 47.3M Q3 '24: 121.8M Q4 '24: 235.2M Q1 '25: -248.4M Q2 '25: -58M Q3 '25: -271.5M Q4 '25: -842.8M Q1 '26: -64.3M Q2 '26: -266.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-750M -500M -250M 0 250M 500M 750M Q3 '21: -588.4M Q4 '21: -443.2M Q1 '22: -364M Q2 '22: -321.6M Q3 '22: -262.3M Q4 '22: -325.3M Q1 '23: -433.6M Q2 '23: -489M Q3 '23: -538.7M Q4 '23: -501M Q1 '24: -533.7M Q2 '24: -396.5M Q3 '24: -352.5M Q4 '24: -205.8M Q1 '25: -547.1M Q2 '25: -300.8M Q3 '25: -244.6M Q4 '25: -205.5M Q1 '26: 175.3M Q2 '26: 111M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-750M -500M -250M 0 250M 500M 750M Q3 '21: -653.3M Q4 '21: -481.7M Q1 '22: -386.9M Q2 '22: -347.7M Q3 '22: -287.3M Q4 '22: -356.2M Q1 '23: -468.3M Q2 '23: -532.6M Q3 '23: -603.8M Q4 '23: -577.1M Q1 '24: -632.7M Q2 '24: -506.8M Q3 '24: -470.4M Q4 '24: -342.7M Q1 '25: -695.3M Q2 '25: -451.5M Q3 '25: -381.1M Q4 '25: -307.5M Q1 '26: 114.9M Q2 '26: 81.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '20: 76.4M Q2 '20: 78M Q3 '20: 78.5K Q1 '21: 79.5K Q2 '21: 79.7K Q3 '21: 79.9K Q1 '22: 87.3M Q2 '22: 87.5M Q3 '22: 87.6M Q1 '23: 88.2M Q2 '23: 88.7M Q3 '23: 88.9M Q1 '24: 99.1M Q2 '24: 99.1M Q3 '24: 100.4M Q1 '25: 97.4M Q2 '25: 106.6M Q3 '25: 100.2M Q1 '26: 121.9M Q2 '26: 105.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '19: -8.56 Q4 '19: -9.67 Q1 '20: -8.83 Q2 '20: -7.02 Q3 '22: -8.22 Q4 '22: -8.03 Q1 '23: -12.69 Q2 '23: -10.31 Q3 '23: -7.83 Q4 '23: -5.80 Q1 '24: 0.43 Q2 '24: 0.77 Q3 '24: 1.57 Q4 '24: 2.28 Q1 '25: -2.69 Q2 '25: -0.87 Q3 '25: -3.01 Q4 '25: -8.44 Q1 '26: -0.96 Q2 '26: -2.90 Q4 '19 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.